The t(10;11)(p13;q14) translocation leads to the fusion of the CALM and AF10 genes. This translocation can be found as the sole cytogenetic abnormality in acute lymphoblastic leukemia, acute myeloid leukemia and in malignant lymphomas. The expression of CALM/AF10 in primary murine bone marrow cells results in the development of an aggressive leukemia in a murine bone marrow transplantation model. Using a yeast two-hybrid screen, we identified the lymphoid regulator Ikaros as an AF10 interacting protein. Interestingly, Ikaros is required for normal development of lymphocytes, and aberrant expression of Ikaros has been found in leukemia. In a murine model, the expression of a dominant negative isoform of Ikaros causes leukemias and lymphomas. The Ikaros interaction domain of AF10 was mapped to the leucine zipper domain of AF10, which is required for malignant transformation both by the CALM/AF10 and the MLL/AF10 fusion proteins. The interaction between AF10 and Ikaros was confirmed by GST pull down and co-immunoprecipitation. Coexpression of CALM/AF10 but not of AF10 alters the subcellular localization of Ikaros in murine fibroblasts. The transcriptional repressor activity of Ikaros is reduced by AF10. These results suggest that CALM/AF10 might interfere with normal Ikaros function, and thereby block lymphoid differentiation in CALM/AF10 positive leukemias.
Introduction
Chromosomal translocations found in leukemia and lymphoma cells are important for the malignant transformation of these cells (Rowley, 1990) . Translocations disturb normal gene function via two different mechanisms, namely transcriptional deregulation or formation of fusion genes (Rabbitts, 1994) .
The recurring t(10;11)(p13;q14) translocation, initially identified in the monocytic cell line U937, leads to the fusion of CALM and AF10 (Kobayashi et al., 1995) . This fusion is observed in acute myeloblastic leukemia (AML), in acute lymphoblastic leukemia (ALL) and in malignant lymphoma and correlates with poor prognosis (Bohlander et al., 2000) . While the CALM/ AF10 fusion comprises nearly the complete sequence of both CALM and AF10, the reciprocal AF10/CALM fusion is essentially a C-terminally truncated AF10 protein ( Figure 1a ). It is very likely that the CALM/ AF10 fusion protein, and not the small reciprocal AF10/ CALM fusion, which cannot be detected in all patients carrying the t(10;11)(p13;q14) translocation, is critical for malignant transformation (Dreyling et al., 1996) . The clathrin assembly lymphoid myeloid leukemia gene (CALM-gene) encodes a 652 amino acid protein that is the ubiquitiously expressed homolog of the neuronspecific adaptor-protein 3. CALM plays an important role in clathrin-mediated endocytosis. CALM is located mainly in the cytoplasm, in particular, in coated pits at the cell membrane and in the Golgi (Tebar et al., 1999) . Recently, CALM was shown to shuttle between the cytoplasm and the nucleus, permitting the interaction with the nucleolar CATS protein (Archangelo et al., 2006) .
The AF10 gene was cloned as the fusion partner of the MLL-gene in AML patients carrying the t(10;11) (p12;q23) translocation (Chaplin et al., 1995) . AF10 encodes a putative zinc-finger transcription factor of 1027 amino acids. Studies in Drosophila with the AF10 homolog dAF10 (alhambra) suggest that it plays a role in heterochromatin-dependent silencing (Linder et al., 2001) . The AF10 protein structure includes an N-terminal LAP/PHD-finger (leukemia associated protein (LAP), plant homeo domain (PHD)) followed by an extended LAP/PHD-finger domain and a nuclear localization signal (Linder et al., 2000) . While this region was also shown to mediate AF10 oligomerization, PHD fingers have recently been shown to bind trimethylated lysine 4 of histone H3 (H3K9Me3) (Martin et al., 2006; Mellor, 2006; Wysocka et al., 2006 ). An AT hook motive in AF10 can bind cruciform DNA. The C-terminal end of AF10 comprises an octapeptide/leucine zipper motive (OMLZ) followed by a glutamine-rich region (Linder et al., 2000) . The OMLZ is required for malignant transformation by both MLL/AF10 and CALM/AF10 and has been shown to interact with the histone methyl transferase DOT1L (DiMartino et al., 2002; Okada et al., 2005 Okada et al., , 2006 . The OMLZ domain was also reported to bind GAS41, a protein which interacts with the INI1 subunit of the SWI/SNF chromatin remodeling complex (Debernardi et al., 2002) . In a murine bone marrow transplantation model, CALM/AF10 causes an aggressive myeloid leukemia. Interestingly, the leukemia propagating cells in these mice show lymphoid characteristics including immunoglobulin heavy chain rearrangement and B220 surface markers (Deshpande et al., 2006) .
To learn more about the transforming potential of AF10 fusions, we performed a yeast two-hybrid screen with the C-terminal part of AF10. One of the prey clones was identified as the lymphoid regulator Ikaros (Georgopoulos et al., 1992; Nietfeld and Meyerhans, 1996; Westman et al., 2002) . The structure of Ikaros comprises an N-terminal DNA-binding domain and a C-terminal oligomerization domain (Figure 1b) . In contrast to the oligomerization domain, the DNA-binding To date 11 Ikaros isoforms have been described. Exons are illustrated as black boxes and white ellipses symbolize zinc-fingers. Important structural elements are the N-terminal DNA binding motif and the C-terminal oligomerization domain. All Ikaros proteins have exons 1, 2 and 7 in common. Isoform 6, which lacks the DNA-binding domain, has a dominant negative effect causing leukemia in a mouse model. The insertion of 60 bp between exons 2 and 3 is unique for murine Ik X and human Ikaros H.
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PA Greif et al domain is not present in dominant negative isoforms of Ikaros (Hahm et al., 1994; Molnar and Georgopoulos, 1994) . The characterisitic nuclear localization of Ikaros at the centromeric heterochromatin requires an intact DNA-binding domain (Sun et al., 1996; Cobb et al., 2000) . Recently, Ikaros isoforms with an insertion of 60 bp between exons 2 and 3 were described in mice and men (Payne et al., 2001 (Payne et al., , 2003 Ronni et al., 2007) . Ikaros interacts with chromatin remodeling factors and is involved in transcriptional regulation and cell cycle control (Kim et al., 1999; Gomez-del Arco et al., 2004 . While in Ikaros knockout mice, B-and T-lymphocyte differentiation is severely defective, mice that are heterozygote for a dominant negative isoform of Ikaros develop leukemias and lymphomas Winandy et al., 1995) . Such dominant negative Ikaros isoforms were also found to be overexpressed in samples from leukemia patients (Sun et al., 1999a-c; Olivero et al., 2000; Rebollo and Schmitt, 2003) . However, it is unknown how the expression of Ikaros is altered during the onset of leukemia. The present study characterizes the interplay between Ikaros and the leukemic fusion protein CALM/AF10.
Results

Identification of AF10 interacting proteins
In order to identify interaction partners of the AF10 protein, we screened a human bone marrow cDNA library using the yeast two-hybrid system. The bait encoded the C-terminal half of AF10 (aa 658-1027) fused to the GAL4 DNA-binding domain (GAL4 DBD). A total of 11 yeast clones, encoding 11 different proteins, were identified that exhibited growth in the absence of histidine and were b-galactosidase positive. One of these clones contained the first two exons of the gene ZNFN1A1 that encodes the key hematopoietic regulator Ikaros. Since Ikaros plays an important role in hematopoiesis and is a potential tumor suppressor gene, we decided to study the AF10 and the CALM/AF10 interaction with Ikaros in detail.
Mapping of the Ikaros interacting domains of AF10
In the yeast two-hybrid screen, we found the N terminus of Ikaros (exon1 þ 2) to interact with the C-terminal part of AF10 (aa 658-1027). To map the minimal Ikaros interaction domain of AF10, several AF10 deletion mutants were fused to GAL4 DBD. After co-transformation of each AF10 deletion mutant together with the Ikaros prey clone, only the leucine zipper domain of AF10 (6) or AF10 mutants that contained the leucine zipper domain (1, 2 and 5) grew on selective plates, indicating protein-protein interaction (Figure 2 ). Thus, we conclude that the leucine zipper domain of AF10 (aa 715-806) is the minimal AF10 domain required for interaction with Ikaros. However, the AF10 mutant representing aa 658-938 did not grow on selective plates, although it contains the leucine zipper domain. This might be explained by unstable protein expression or a special three-dimensional structure of this mutant that interferes with the interaction. Interestingly, the AF10 leucine zipper is known to be required for both MLL/ AF10 and CALM/AF10 dependent leukemogenesis (DiMartino et al., 2002; Okada et al., 2006) .
Confirmation of the AF10-Ikaros interaction in vitro and in vivo
To confirm the interaction between AF10 and Ikaros in vitro, we performed glutathione S-transferase (GST) 
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PA Greif et al pull-down assays. To this end, both AF10 and Ikaros were expressed as GST fusion proteins in bacteria and immobilized on glutathione beads (Figures 3a and b) . The beads were then incubated with nuclear extracts from human endothelial kidney cells (HEK 293T) that transiently overexpressed either FLAG-tagged AF10 or HA-tagged Ikaros (isoform 1, also described as isoform VI). While FLAG-AF10 binds to GST-Ikaros and HA-Ikaros binds to GST-AF10, no binding of FLAG-AF10 to the GST-control is seen and only minimal amounts of HA-Ikaros bind nonspecifically to GST (Figures 3c and d ). This nonspecific binding might be explained by the fact that at least 10 times more GST was bound to the glutathione beads than GST-AF10 ( Figure 3a ). FLAG-AF10 also binds to GST-AF10, which is consistent with the previously reported AF10 dimerization (Linder et al., 2000) .
In vivo interaction was confirmed by co-immunoprecipitation experiments with FLAG-AF10 and HA-Ikaros after transient coexpression in HEK 293T cells. FLAG-AF10 is immunoprecipitated and HAIkaros is co-immunoprecipitated by antibodies against either AF10 or FLAG (Figure 4 ). It could also be shown that immunoprecipitation of HA-Ikaros with HAantibodies will co-immunoprecipitate FLAG-AF10. In contrast, neither the rat isotype control antibody nor normal mouse immunoglobulin G (IgG) precipitate these proteins.
CALM/AF10 alters the subcellular localization of Ikaros
To learn more about the interaction between AF10 and Ikaros on the cellular level, we performed in vivo localization experiments using immunofluorescence of Ikaros in combination with either AF10 or CALM/ AF10. After co-transfections of NIH3T3 mouse fibroblasts, AF10 shows a diffuse nuclear distribution that is partially overlapping with the exclusively chromocentric localization of Ikaros (Figure 5a ). Chromocenters are the DAPI bright regions seen in mouse fibroblast which 
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PA Greif et al result from dense centromeric heterochromatin. Interestingly, in the presence of cytoplasmic CALM/AF10, Ikaros shows an altered localization that is both nuclear and cytoplasmic in some cells (Figure 5b ). In these cells, CALM/AF10 and Ikaros colocalize in the cytoplasm.
AF10 reduces the transcriptional repression of Ikaros
Since Ikaros is known to act as a repressor of transcription when fused to a GAL4 DNA-binding domain, we tested the influence of AF10 and CALM/ AF10 on Ikaros' repressor function using a constitutive active GAL4-tk-luciferase reporter ( Figure 6 ). While similar background activity of the reporter is observed with AF10 together with GAL4-DBD compared to GAL4-DBD alone, we observed a twofold increase of the background activity with CALM/AF10 together with GAL4-DBD (Figure 6a ). Coexpression of GAL4-DBD-Ikaros and AF10 reduces the Ikaros-mediated repression from approximately 17-to 9-fold (Figure 6b ). Coexpression of CALM/AF10 also reduced Ikarosmediated repression to approximately 11-fold. Furthermore, we tested the ability of Ikaros to activate a luciferase reporter with a specific Ikaros binding site (Koipally et al., 2002) ; however, in our hands Ikaros did not activate such reporter plasmid (4xIkBS2-tk-LUC) in several cell lines tested including NIH3T3 cells and HEK293T cells (data not shown).
Differential expression of Ikaros in leukemia patient samples
To study the expression of Ikaros in CALM/AF10 positive cells, we analysed bone marrow samples from leukemia patients using microarray chips. Comparing various subtypes of leukemia and normal bone marrow, Ikaros was found to be expressed in all groups with the highest levels in pro-ALL and lowest levels in AML with complex aberrant karyotype. No significant differences between CALM/AF10 positive leukemias and other types of leukemia were observed ( Figure 7 ).
Discussion
We have shown that AF10 interacts with the lymphoid transcriptional regulator Ikaros in vitro and in vivo. The Ikaros interaction domain was mapped to the OMLZ domain of AF10, which is essential for malignant transformation by both CALM/AF10 and MLL/AF10 (DiMartino et al., 2002; Okada et al., 2006) . Regarding the potential tumor suppressor function of Ikaros, we suggest that this novel protein-protein interaction might play an important role in CALM/AF10-and MLL/ AF10-induced leukemias.
While nuclear AF10 colocalizes with nuclear Ikaros foci at the chromocenters, in certain cells that express cytoplasmic CALM/AF10, an altered distribution of Ikaros both in the nucleus and the cytoplasm was found. In these cells, the cytoplasmic portion of Ikaros colocalizes with CALM/AF10. Thus, CALM/AF10 might have a dominant negative effect on Ikaros' function as transcription factor by altering the heterochromatic localization of Ikaros in the cell nucleus and sequestering Ikaros in the cytoplasm. In fact, to exert repression of target genes, Ikaros relies on binding of pericentromeric heterochromatin (Trinh et al., 2001) . Interestingly, the CALM/AF10 leukemia propagating cell shows lymphoid characteristics in a murine bone marrow transplantation model, even though the majority of leukemic blasts have a myeloid phenotype in this model (Deshpande et al., 2006) . Since Ikaros is necessary for normal B-and T-cell development Yoshida et al., 2006) , it is tempting to propose that CALM/AF10 may block lymphoid differentiation through interaction with Ikaros ( Figure 8 ). The myeloid characteristics of the leukemic cells would be the result of a default differentiation along the evolutionarily older myeloid lineage. The interaction between CALM/AF10 and Ikaros might also be the underlying cause of impaired thymocyte differentiation in transgenic CALM/AF10 mice (Caudell et al., 2007) . In particular, CALM/AF10 may disturb the equilibrium between different Ikaros isoforms. In a current model, dominant negative isoforms of Ikaros, lacking a functional DNA-binding domain, trigger leukemia through oligomerization with wild-type Ikaros protein (Winandy et al., 1995; Westman et al., 2002) . Similar to dominant negative Ikaros isoforms, CALM/AF10 may also disturb the formation of Ikaros homodimers that are essential for the recruitment of Ikaros target genes into pericentromeric heterochromatin. Since we found AF10 to interact with the protein domain encoded by exons 1 and 2 of Ikaros, AF10 has the potential to bind all Ikaros isoforms. However, it cannot be ruled out that CALM/AF10 binds preferentially to some Ikaros isoforms. Other nuclear interactors of CALM/AF10, namely CATS and DOT1L, were shown to recruit CALM/AF10 to the nucleus upon coexpression (Archangelo et al., 2006; Okada et al., 2006) . Since CALM/AF10 shuttles between the nucleus and the cytoplasm it may be retained in the nucleus by interacting proteins (Archangelo et al., 2006) . In the present study, we report that Ikaros, which relies on its ability to bind DNA for its nuclear localization Sun et al., 1996; Cobb et al., 2000) , colocalizes with CALM/AF10 in the cytoplasm. Thus, cytoplasmic localization of Ikaros through interaction with CALM/AF10 would result in decreased DNA binding of Ikaros.
In reporter gene assays, we found that AF10 reduces the transcriptional repression exerted by Ikaros. It is likely that the ability of AF10 to activate transcription (DiMartino et al., 2002) antagonizes Ikaros-mediated transcriptional repression. We also found CALM/AF10 to reduce Ikaros-mediated transcriptional repression; however, we cannot rule out that this might be an additive effect since CALM/AF10 increased the background levels of the luciferase reporter. Considering that both AF10 and Ikaros are associated with heterochromatin (Brown et al., 1997; Cobb et al., 2000; Linder et al., 2001) , the CALM/AF10 fusion may interfere with a potential role of AF10 as counter player of Ikaros in heterochromatin regulation. Thus, aberrant targeting of Ikaros by CALM/AF10 might be an important mechanism in CALM/AF10 induced leukemia.
Our microarray expression profiles showed that Ikaros transcripts and presumably the Ikaros protein are present in the cells of CALM/AF10 positive AML patients. Ikaros protein would therefore be available for interaction with CALM/AF10. However, there was no significant deregulation of median Ikaros expression compared to other subtypes of AML. Aberrant expression levels of Ikaros isoforms in leukemia have been reported (Sun et al., 1999a-c; Olivero et al., 2000; Rebollo and Schmitt, 2003) . Unfortunately, the DNA microarray technique used does not provide information about the expression levels of individual Ikaros isoforms.
In summary, we provide evidence for a novel interaction between the leukemia-associated fusion protein CALM/AF10 and the lymphoid regulator Ikaros. We further propose that CALM/AF10 may disturb the tumor suppressor function and lineage determination properties of Ikaros through altering its subcellular localization. It is intriguing to speculate that CALM/AF10 might have an influence on the exact level of Ikaros activity in the nucleus by sequestering a fraction of Ikaros to the cytoplasm. Recently, it has become apparent that the 'dosage window' of nuclear factors is critical for the process of hematopoietic differentiation and leukemogenesis. For example, lowering the levels of the Ets transcription factor PU.1 to just 20% of normal levels will result in leukemia while the complete absence of PU.1 does not lead to the development of leukemia in knockout mice (Rosenbauer et al., 2004) . More studies will be required to understand the role that the CALM/AF10 Ikaros interaction plays in the development of leukemia.
Materials and methods
Plasmid construction
The bait plasmids for the yeast two-hybrid screen were constructed by inserting the full-length or various portions of the AF10 cDNA in frame into pGBKT7 (Clontech, Mountain View, CA, USA). The pGBKT7/AF10 plasmids express AF10 or AF10 fragments as a fusion gene with the yeast GAL4 DNA-binding domain (aa 1-147 of GAL4). The following portions of AF10 were cloned in-frame with the GAL4 DNA-binding domain (aa 1-147) into yeast expression vector pGBKT7: (1) aa 1-1027 (full-length); (2) D382-681 (lacking aa 283-681)); (3) aa 1-381; (4) 382-681; (5) aa 658-938; (6) aa 658-1027; (7) aa 715-806; (8) aa 807-1027. For GST pull-down assays, AF10 was cloned into the pGex4T1 vector (Amersham Pharmacia Biotech, GE Healthcare, Uppsala, Sweden) using the restriction enzymes SalI and NotI. The pcDNA3-HA-Ikaros-VI plasmid was a gift from Dr Steven Smale (Los Angeles). The FLAG-AF10 and FLAG-CALM/AF10 expression constructs for mammalian cells were provided by Dr Guoliang Xu (Shanghai). The tk-4xIkaros-binding-site-CAT reporter plasmid, the GST-Ikaros expression vector for bacteria and the GAL4 DBD-Ikaros expression vector for mammalian cells were received from Dr Katia Georgopoulos (Boston). The tk-4xIkaros-binding-site was PCR amplified using linker primers (forward: 5 0 -GCATGAGC TCACGACGGCCAGTGCCAAGC-3 0 and reverse 5 0 -CAA 
AF10 interacts with Ikaros
PA Greif et al GCTCCTCGAGATCTGCG-3 0 ) and inserted into the pGL2-basic luciferase reporter plasmid (Promega, Madison, WI, USA) using restriction enzymes SacI and XhoI. The 5xGAL4-tk-LUC reporter plasmid was provided by Dr Christian Netzer (Ko¨ln).
Yeast two-hybrid screen The Yeast strain AH109 (Clontech) was transformed in parallel with the pGBKT7/AF10 bait plasmid (encoding the C-terminal aa 658-1027 of AF10) and with a bone marrow library cloned into pACT2 (Clontech) (prey plasmids) using the lithium-acetate procedure. The resulting bait and prey strains were mated and spread on plates with selective medium. Colonies growing on dropout plates lacking leucine, tryptophan and histidine supplemented with 20 mM 3-amino-1,2,4-triazole (3-AT) and exhibiting a positive b-galactosidase reaction were selected for further analysis.
Mapping of interacting domains
To map the protein interaction domains of AF10 and Ikaros, yeast strain AH109 was co-transformed with the AF10 deletion mutants cloned into pGBKT7 and the pACT2-Ikaros prey plasmid. Growth was assayed on dropout plates lacking leucine and tryptophan (ÀL, ÀW: transformation control) and interactions were scored on dropout plates supplemented with 20 mM 3-AT lacking leucine, tryptophan and histidine (ÀL, ÀW, ÀH: interaction assay).
Transfection of mammalian cells and preparation of nuclear extracts A total of 1 Â 10 6 HEK 293T cells were grown in 100 mm dishes and transiently transfected using 10 mg plasmid DNA and 15 mg polyethyleneimine (Sigma, St Louis, MO, USA). Cells were harvested after 24 h and nuclear extracts were prepared using 400 ml hypotonic buffer (10 mM HEPES pH 7.5, 1.5 mm MgCl 2 , 10mM NaCl, 0.5 mM dithiothreitol, 4 ml protease inhibitor cocktail (Sigma)) for lysis of the cytoplasm and 100 ml hypertonic buffer (20 mM HEPES-KOH pH 7.5, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, 1 ml protease inhibitor cocktail (Sigma)) for lysis of the nucleus as described by Andrews and Faller (1991) . Nuclear extracts were then used freshly for GST pull downs or immunoprecipitation experiments.
Generation of monoclonal antibodies against AF10
In cooperation with Dr E Kremmer (GSF, Mu¨nchen) and Dr HR Rackwitz (PSL GmbH, Heidelberg) two AF10 peptides, namely AF1 (aa 425-442, AVTSQPKSFENSPGDLGN) and AF2 (aa 624-642, SLSQAPSHMYGNRSNSSMAA) were synthesized and used to immunize rats. Antibody-secreting hybridoma cells were produced by fusing the spleen cells from the immunized rats with myeloma cells. Successfully fused cells were propagated in selective medium and screened for antibody production. Using ELISA and western blot five productive hybridoma clones were identified to specifically detect the AF1 peptide (5H11, 5E6, 8A6, 6A4, 6H6) and one productive hybridoma clone was identified to specifically detect the AF2 peptide (5F6). Productive hybridoma clones were expanded and cloned to establish monoclonal hybridoma cell lines. Supernatants of these cell lines were used for western blots and immunoprecipitation.
GST pull down
The GST-AF10 and GST-Ikaros were expressed in Escherichia coli strain XL1 blue (Stratagene, La Jolla, CA, USA) and purified from bacterial proteins by incubation with glutathione sepharose 4B beads (Amersham Pharmacia Biotech). About 20 ml of nuclear extract from HEK293T cells, transfected with pcDNA-HA-Ikaros or pcDNA-FLAG-AF10 as described above, was incubated with 10 ml of sepharose bound GST fusion proteins or sepharose bound GST as control in 100 ml protein-binding buffer (20 mM Tris pH 7.6, 150 mM NaCl, 0.1% NP-40). After extensive washing of the beads with binding buffer, the beads were boiled and separated on a 10% sodium dodecyl sulphate (SDS)-PAGE gel and subsequently analysed by western blot using monoclonal antibodies against HA (3F10, Roche, Basel, Switzerland) and monoclonal anti-FLAG M2 antibodies (Sigma) for detection of HA-Ikaros and FLAG-AF10, respectively.
Immunoprecipitation About 20 ml of freshly prepared nuclear extract from HEK293T cells, co-transfected with pcDNA-HA-Ikaros and pcDNA3-FLAG-AF10, were used for each immunoprecipitation experiment. Nuclear extract was incubated in 100 ml protein binding buffer (20 mM Tris pH 7.6, 150 mM NaCl, 0.1% NP-40) together with the following antibodies: (1) 6 mg monoclonal mouse anti-FLAG M2 (Sigma); (2) 6 mg normal mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA); (3) 100 ml monoclonal rat anti-AF10 (clone 5F6, culture supernatant provided by Dr E Kremmer, GSF); (4) 100 ml isotype control antibodies (culture supernatant provided by Dr E Kremmer, GSF); (5) 0.1 mg monoclonal rat anti-HA (3F10, Roche). After 1 h incubation at 4 1C on a rotating wheel, 10 ml Protein G-agarose beads (Roche) were added to each reaction and incubation was continued for another hour. Beads were washed extensively with binding buffer, resuspended in SDSsample buffer, boiled and separated on a 10% SDS-PAGE. Subsequent western blot analysis was performed with the above-described antibodies against FLAG or HA to detect precipitated FLAG-AF10 or HA-Ikaros, respectively.
Immunoblotting analysis
Immunocomplexes and cellular lysates were electrophoresed on 6-12% SDS-PAGE and transferred to PVDF membrane (Hybond P, Amersham Pharmacia Biotech). The membranes were blocked for 30 min with 5% nonfat dried milk at room temperature and probed with the above-described specific antibodies, followed by secondary antibodies conjugated to horseradish peroxidase. Proteins were detected with enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).
Coomassie blue staining After separation of protein samples by SDS-PAGE gels were put in fixing solution (10% acetic acid, 40% methanol) for 15 min. Gels were then stained with Coomassie blue solution (Bio-Rad, Hercules, CA, USA) for 1 h and subsequently destained with fixing solution until the blue background color was completely removed.
Immunostaining and confocal laser scanning fluorescence microscopy For intracellular localization studies, NIH3T3 mouse fibroblasts were grown on coverslips and co-transfected with FLAG-AF10 or FLAG-CALM/AF10 and HA-Ikaros plasmids as described above. After 24 h, cells were fixed with phosphate-buffered saline (PBS) 2% paraformaldehyde for 10 min, permeabilized with PBS 0.1% Triton X for 10 min and blocked with PBS 10% fetal calf serum (FCS) for 1 h. Coverslips were incubated with polyclonal rabbit Ikaros antibodies (gift from Steven Smale, Los Angeles) overnight and monoclonal mouse FLAG antibodies (Sigma). Following extensive washing with PBS 0.1% Tween, Alexa 555 and Alexa 488-conjugated secondary antibodies were added for 1 h. After further washing steps, cells were stained with DAPI and mounted using Cytomat medium (DAKO, Glostrup, Denmark). Finally, immunostained species were analysed in a confocal fluorescence laser scanning system (TCS-SP2 scanning system and DM IRB inverted microscope, Leica, Solms, Germany).
Reporter gene assays 293T cells or NIH 3T3 cells were seeded in 24-well plates and co-transfected with 100 ng of the pGAL4-tk-LUC reporter plasmid, 10 ng of p-tk-RL co-reporter vector (Promega), 100 ng of GAL4-DBD-Ikaros or GAL4-DBD only expression plasmids, 400 ng of pcDNA-FLAG-AF10, pcDNA-FLAG-CALM/AF10 or pcDNA empty vector. The total amount of transfected DNA in each well was kept constant by adding pcDNA empty vector. After 48 h, cells were harvested and assayed for firefly and Renilla luciferase activities using a Dual-Luciferase Reporter Assay System (Promega). Measurements of Renilla luciferase activity were used for normalization. Experiments were performed in triplicates and all samples were measured twice.
Expression analysis of Ikaros in leukemia samples
Total mRNA was isolated from patient samples, processed and analysed on the Affymetrix HG-U133A and HG-U133B chips as described before (Schoch et al., 2002) . The CEL file data from the samples used in the comparison were normalized together according to the procedure described by Huber et al. (2002) . Normalized expression data were then analysed with the R software package and the 'boxplot' function (www. r-project.org). Expression signal intensities are given on a logarithmic scale. A total of 10 samples from each leukemic subgroup as well as 10 normal bone marrow samples were included in the analysis.
